Table 2 Performance evaluation of the HIDEEP per the size of unlabeled datasets (AUROC).

From: HIDEEP: a systems approach to predict hormone impacts on drug efficacy based on effect paths

No.

Disease

AUROC

1 times

3 times

5 times

7 times

10 times

1

Acute Kidney Injury

0.92

0.95

0.95

0.96

0.94

2

Angina Pectoris

0.87

0.87

0.87

0.87

0.87

3

Atrial Fibrillation

0.77

0.76

0.76

0.78

0.77

4

Breast Neoplasms

0.81

0.80

0.80

0.76

0.79

5

Colonic Neoplasms

0.89

0.91

0.90

0.87

0.90

6

Diabetes Mellitus, Type 2

0.76

0.73

0.76

0.74

0.74

7

Diabetic Nephropathies

0.84

0.87

0.88

0.89

0.86

8

Heart Failure

0.95

0.94

0.92

0.93

0.93

9

Hyperalgesia

0.91

0.95

0.93

0.94

0.93

10

Hyperglycemia

0.96

0.98

0.98

0.98

0.97

11

Hypertension

0.85

0.87

0.89

0.88

0.87

12

Hypotension

0.92

0.92

0.91

0.91

0.93

13

Lung Neoplasms

0.89

0.93

0.92

0.95

0.95

14

Myocardial Infarction

0.91

0.91

0.91

0.90

0.92

15

Ovarian Neoplasms

0.94

0.98

0.97

0.96

0.98

16

Postoperative Complications

0.92

0.94

0.92

0.92

0.90

17

Prostatic Neoplasms

0.93

0.86

0.85

0.85

0.86

18

Seizures

0.84

0.83

0.83

0.82

0.83

19

Tachycardia

0.93

0.90

0.91

0.90

0.91

20

Venous Thromboembolism

0.91

0.93

0.90

0.91

0.89

 

Average

0.89

0.89

0.89

0.89

0.89